| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
178.65(B) |
| Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
| 52
Week Range: |
$217.36 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
| Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
1 |
1 |
4 |
8 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Harper Sean E |
EVP, Research & Development |
• • – |
2018-01-31 |
4 |
D |
$191.27 |
$115,910 |
D/D |
(606) |
53,614 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2018-01-31 |
4 |
D |
$191.27 |
$25,248 |
D/D |
(132) |
21,113 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2018-01-31 |
4 |
D |
$191.27 |
$500,362 |
D/D |
(2,616) |
392,982 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$26,334 |
D/D |
(133) |
31,594 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$113,850 |
D/D |
(575) |
203,134 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$89,694 |
D/D |
(453) |
54,200 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$21,582 |
D/D |
(109) |
21,245 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$303,534 |
D/D |
(1,533) |
395,598 |
|
- |
|
| Meline David W |
EVP & CFO |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$98,208 |
D/D |
(496) |
47,795 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$30,294 |
D/D |
(153) |
33,443 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2018-01-16 |
4 |
AS |
$185.62 |
$283,071 |
D/D |
(1,525) |
54,673 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2017-12-12 |
4 |
AS |
$176.83 |
$269,666 |
D/D |
(1,525) |
56,106 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2017-11-13 |
4 |
AS |
$171.58 |
$261,660 |
D/D |
(1,525) |
57,631 |
|
- |
|
| De Carbonnel Francois |
Director |
• • – |
2017-11-08 |
4 |
S |
$173.61 |
$694,422 |
D/D |
(4,000) |
15,528 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2017-10-09 |
4 |
AS |
$185.95 |
$283,574 |
D/D |
(1,525) |
59,156 |
|
- |
|
| Graham Jonathan P |
SVP, Gen. Counsel & Secy. |
• • – |
2017-08-04 |
4 |
D |
$174.18 |
$1,175,192 |
D/D |
(6,747) |
44,165 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2017-08-02 |
4 |
D |
$174.13 |
$111,269 |
D/D |
(639) |
31,478 |
|
- |
|
| Meline David W |
EVP & CFO |
• • – |
2017-08-01 |
4 |
D |
$174.51 |
$1,319,645 |
D/D |
(7,562) |
47,920 |
|
- |
|
| Baltimore David |
Director |
• • – |
2017-05-31 |
4 |
S |
$153.93 |
$569,541 |
D/D |
(3,700) |
31,159 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2017-05-24 |
4 |
S |
$154.40 |
$451,164 |
D/D |
(2,922) |
21,292 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2017-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
346 |
24,214 |
|
- |
|
| Such Annette Louise |
VP, Finance and CAO |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
615 |
8,478 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,444 |
34,144 |
|
- |
|
| Meline David W |
EVP & CFO |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,305 |
55,227 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
984 |
33,533 |
|
- |
|
2206 Records found
|
|
Page 26 of 89 |
|
|
0.67 (0.22%) 
